Key result
Losartan use in patients with mild COVID-19 and moderate arterial hypertension was associated with improved general condition, blood coagulation, and immune response compared to no treatment.
Why the study?
This study investigated how high altitude affects angiotensin regulatory systems in susceptible patients with COVID-19.
Does losartan improve clinical, immunological, and coagulation parameters in patients with COVID-19 and arterial hypertension under high-altitude conditions?
Cohort (n=335)
Does losartan improve clinical, immunological, and coagulation parameters in patients with COVID-19 and arterial hypertension under high-altitude conditions?
Losartan use in patients with COVID-19 and arterial hypertension under high-altitude conditions was associated with improved clinical, coagulation, and immunological parameters, though limited by baseline differences in COVID-19 severity between groups.
Answers are grounded in this paper and cite their sources.
High-altitude exposure may alter angiotensin regulation in COVID-19; leaves open effects on outcomes in susceptible populations.
Background: A number of studies on the mechanisms of the positive effect of angiotensin (Ang) converting enzyme type 2 (ACE2) on the general condition of patients with coronavirus disease (COVID-19)reflect its direct correlation with the ACE2 concentration. This study investigated how the high-altitude factor affects angiotensin regulatory systems in patients with COVID-19 in susceptible populations.Materials and Methods: A prospective cohort study of 335 patients with COVID-19 and concomitant arterial hypertension determined general clinical, immunological, and other parameters of health status. Group Iincluded 135 patients of both genders with moderate COVID-19 caused by SARS-CoV-2 and moderate arterial hypertension (AH) who refused anti-hypertensive drugs. Losartan was given to 200 patients of bothgenders with a laboratory-confirmed mild SARS-CoV-2 infection and moderate AH in Group II.Results: Comparing Group II to Group I, the general condition parameters were found to be noticeably improved in Group II. Additionally, patients in Group II showed positive blood coagulation system dynamics. When comparing Groups I and II, the immune response was seen to be more stable in Group II.Conclusions: Group I patients with ACE2 deficiency set off a chain of events, most of which had to do with how Ang II affected the body by turning on angiotensin type 1 receptors. Observations made inGroup II showed a favourable response to Ang-(1–7) and its effects on angiotensin type 2 receptors, Mas receptors, and the lowering of ACE2 bradykinin, blocking the implementation of the pro-inflammatoryaction through B1 receptors. How to cite this article:Alymkulov A, Tagaev T, Vityala Y. Role, Impact, and Effect of Angiotensin-converting Enzyme 2 (ACE2)in Patients with COVID-19 under High-altitude Conditions. J Commun Dis. 2023;55(3):83-89. DOI: https://doi.org/10.24321/0019.5138.202343
No takes yet. Share an insight, caveat, or question.
Yethindra Vityala (2023) conducted a cohort in COVID-19 and concomitant arterial hypertension (n=335). Losartan vs. Refusal of anti-hypertensive drugs was evaluated on General condition parameters, blood coagulation system dynamics, and immune response. Losartan use in patients with mild COVID-19 and moderate arterial hypertension was associated with improved general condition, blood coagulation, and immune response compared to no treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: